002107 Shandong Wohua Pharmaceutical
- 5.16
- +0.08+1.57%
Shandong Wohua Pharmaceutical News
Wohua Pharmaceuticals: Report for the third quarter of 2024
Shandong Wohua Pharmaceutical: Half-year report for the year 2024.
Shandong Wohua Pharmaceutical: Summary of Half-Year Report in 2024.
Express News | Shandong Wohua Pharmaceutical: Net income in the first half of 2024 decreased by 70.21% year-on-year.
Shandong Wohua Pharmaceutical: 2024 Interim Performance Forecast
Shandong Wohua Pharmaceutical (002107.SZ): net income is expected to decrease by 64.52%-76.08% in the first half of the year.
On July 10th, Gelunhui reported that the net income attributed to shareholders of Shandong Wohua Pharmaceutical (002107.SZ) for the first half of 2024 is expected to be between 8.9 million yuan and 13.2 million yuan, a decrease ranging from 76.08% to 64.52% year-on-year. After deducting non-recurring gains and losses, the net income is expected to be between 8.2 million yuan and 12 million yuan, a decrease ranging from 77.02% to 66.38% year-on-year; the basic EPS is expected to be 0.0154 yuan/share to 0.0229 yuan/share. The company's core product, Wohua@Xin Keshu Tablet, will be released in 2023.
Wohua Pharmaceutical (002107.SZ) 2023 equity distribution: 2.5 yuan for every 10 shares. The share registration date is May 23
Wohua Pharmaceutical (002107.SZ) issued an announcement. The company's 2023 equity distribution plan is: to all shares...
Wohua Pharmaceutical (002107.SZ): Net profit of 9.6672 million yuan in the first quarter decreased by 62.01% year-on-year
Gelonghui, April 26 | Wohua Pharmaceutical (002107.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 215 million yuan, down 8.49% year on year; net profit attributable to shareholders of listed companies was 9.6672 million yuan, down 62.01% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 8.225,800 yuan, down 66.80% year on year; basic earnings per share were 0.02 yuan.
Wohua Pharmaceutical (002107.SZ) received the “Advance Notice of Administrative Penalty”
Wohua Pharmaceutical (002107.SZ) issued an announcement. Recently, the company received the “Advance Notice of Administrative Penalty” (penalty word [Wohua Pharmaceutical (002107.SZ) received the “Advance Notice of Administrative Punishment”] No. 3) issued by the Shandong Regulatory Bureau of the China Securities Regulatory Commission. The relevant details are now announced as follows.
Wohua Pharmaceutical (002107.SZ): Net profit for 2023 fell 45.27% to 587.671 million yuan, and plans to pay 10 2.5 yuan
Gelonghui, March 29 | Wohua Pharmaceutical (002107.SZ) announced its 2023 annual report. In 2023, the company achieved operating income of 909.5 million yuan, a year-on-year decrease of 10.38%; net profit attributable to shareholders of listed companies was 587.671 million yuan, a year-on-year decrease of 45.27%; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 568.975 million yuan, a year-on-year decrease of 45.69%; basic income per share is 0.10 yuan; plans to distribute a cash dividend of 2.50 yuan (tax included) for every 10 shares to all shareholders.
Wohua Pharmaceutical (002107.SZ): As of January 10, 2024, the number of company owners was 38,953
Gelonghui, March 13 | Wohua Pharmaceutical (002107.SZ) said on the investor interactive platform that as of January 10, 2024, the number of company owners was 38,953.
Wohua Pharmaceutical (002107.SZ) received a warning letter from the Shandong Securities Regulatory Bureau
Wohua Pharmaceutical (002107.SZ) announced that the company recently received the China Securities Regulatory Commission from the Shandong Regulatory Bureau...
Changes in the A-share Chinese medicine sector boosted, and Wohua Pharma hit a rise and stop
Gelonghui, December 11 | Wohua Pharmaceutical hit a rise and fall, Kangyuan Pharmaceutical surged 7%, and Tianshili, Da Rentang, and China Resources 39 followed suit. According to the news, in order to deal with the high incidence of mycoplasma pneumoniae infections, Jin Zhen oral solution developed by Kangyuan Pharmaceutical has become a “traditional Chinese medicine option” for treatment. Eling Pharmaceutical has also initiated clinical trials on the efficacy and safety of Lianhua Qingfeng granules in treating mycoplasma pneumonia in children.
Zhao Bingxian, the actual controller of Wohua Pharmaceutical (002107.SZ), has been lifted from the lien measures by the relevant discipline inspection and supervision authorities
Wohua Pharmaceutical (002107.SZ) issued an announcement. On November 7, 2023, the company issued “Shandong Wohua...
Zhao Bingxian, the actual controller of Wohua Pharmaceutical and “China Buffett”, was detained. Company: I don't know
Gelonghui, November 6 | According to the interface, it was learned from multiple sources that Zhao Bingxian, chairman of Shandong Wohua Pharmaceutical Technology Co., Ltd., known as “China Buffett,” was detained by relevant parties in early July 2023. People familiar with the matter said that until now, Zhao Bingxian had always been in Hong Kong, and the company affairs were carried out by her “remote control” sister, Zhao Caixia. After returning to the mainland for the last time, Cho Bing-hyeon discovered that she had been “controlled by the border” when she left. Unexpectedly, she was controlled soon after. The reporter telephoned Wohua Pharmaceutical's administration department. The other party said they did not understand the detention of Cho Bing-hyeon, and said they would respond after further inquiries.
Wohua Pharmaceuticals: Net profit for the first half of 2023 fell 33.66% year on year
On July 28, GLONGHUA PHARMACEUTICAL released its semi-annual report. The company achieved operating income of 492 million yuan for the half year of 2023, down 2.24% year on year; net profit of 37.204 million yuan, down 33.66% year on year; and basic earnings per share of 0.06 yuan.
Wohua Pharmaceuticals (002107.SZ): Net profit in the first half of the year fell 33.66% to 37.203.99 million yuan
On July 28, GLONGHUA PHARMACEUTICAL (002107.SZ) released its 2023 semi-annual report. Operating income for the reporting period was 492 million yuan, down 2.24% year on year; net profit attributable to shareholders of listed companies was 37.203.99 million yuan, down 33.66% year on year; net profit attributable to shareholders of listed companies deducted non-recurring profit and loss was 356.8995 million yuan, down 36.02% year on year; basic earnings per share was 0.06 yuan.
Wohua Pharmaceutical: Xinkeshu tablets selected from the national collection of proprietary Chinese medicines
On July 7, GLONGHUA PHARMACEUTICAL announced that on July 5, the National Proprietary Chinese Medicine Joint Procurement Office issued the “National Proprietary Chinese Medicine Alliance Procurement Notice (No. 4)”. The company's product, Xinke Shu tablets, were selected; the selection price was 18.83 yuan/box. Xinkexu tablets are a national basic drug catalogue product, a medical insurance category A product, and one of the company's four exclusive pillar products. The selected price has dropped significantly compared to the original benchmark price, which may put some pressure on sales performance, but it is beneficial to improving drug accessibility, speeding up product access, and increasing brand influence.
Wohua Pharmaceutical (002107.SZ): There is significant uncertainty about the company's control rights due to actual controller property disputes
According to the Zhitong Finance App, Wohua Pharmaceutical (002107.SZ) issued an announcement. The company received a notice from the actual controller, Zhao Bingxian, and learned that the Beijing Tongzhou District People's Court handed down a civil judgment on the property dispute case between Zhao Bingxian and Lu Juan after their divorce on June 1, 2023 (hereinafter referred to as the first instance judgment). The first instance judgment divided the shares of Beijing China Securities Wanrong Investment Group Co., Ltd. (hereinafter referred to as China Securities Wanrong), the controlling shareholder of the company, divided equally between the two parties. Zhao Bingxian will file an appeal according to law within 15 days of receiving the first instance verdict. As of the date of this announcement, among the controlling shareholders of the company
Wohua Pharmaceutical (002107.SZ): Net profit of 25.45 million yuan in the first quarter fell 5.35% year-on-year
Gelonhui, April 26, 丨 Wohua Pharmaceutical (002107.SZ) disclosed its first-quarter report, with operating income of 235 million yuan, a year-on-year decrease of 9.29%, net profit of 25.45 million yuan, a year-on-year decrease of 5.35%, after deducting non-net profit of 24.78 million yuan, a year-on-year decrease of 6.54%, and basic earnings per share of 0.04 yuan.
Analysis
Price Target
No Data
No Data